Cargando…

T‐box transcription factor 2 mediates antitumor immune response in cutaneous squamous cell carcinoma by regulating the expression of programmed death ligand 1

BACKGROUND: Cutaneous squamous cell carcinoma (CSCC) is the second largest nonmelanoma skin cancer in humans; effective treatment options for metastatic CSCC are still in short. In this study, we aimed to explore the function of T‐box transcription factor 2 (TBX2) in CSCC. METHODS: The expression le...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xu, Li, Zhi, Sun, Yadi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9838745/ https://www.ncbi.nlm.nih.gov/pubmed/36478592 http://dx.doi.org/10.1111/srt.13254

Ejemplares similares

Expression of Programmed Death-Ligand 1 in Cutaneous Squamous Cell Carcinoma Arising in Sun-Exposed and Nonsun-Exposed Skin
por: Goto, Hiroyuki, et al.
Publicado: (2020)

Blockade of programmed death-1/programmed death ligand pathway enhances the antitumor immunity of human invariant natural killer T cells
por: Kamata, Toshiko, et al.
Publicado: (2016)

Programmed Death Ligand 1 Expression in Laryngeal Squamous Cell Carcinomas and Prognosis
por: Batur, Sebnem, et al.
Publicado: (2020)

Antitumor Effect of Albendazole on Cutaneous Squamous Cell Carcinoma (SCC) Cells
por: Zhang, Qing-Ling, et al.
Publicado: (2019)

Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma
por: Chen, Kaiyan, et al.
Publicado: (2016)

Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage
por: Hira-Miyazawa, Mayuko, et al.
Publicado: (2017)

Distinct prognostic values of programmed death-ligand 1 and programmed cell death protein 1 in lung adenocarcinoma and squamous cell carcinoma patients
por: Wang, Shuo, et al.
Publicado: (2021)

Inflammation promotes oral squamous carcinoma immune evasion via induced programmed death ligand-1 surface expression
por: LU, WANLU, et al.
Publicado: (2013)

Editorial: Progress of programmed cell death in antitumor immunity
por: Yan, Fangfang, et al.
Publicado: (2023)

Decreased Expression of Programmed Death Ligand-L1 by Seven in Absentia Homolog 2 in Cholangiocarcinoma Enhances T-Cell–Mediated Antitumor Activity
por: Zheng, Hao, et al.
Publicado: (2022)

Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma
por: Kim, Ryul, et al.
Publicado: (2016)

Programmed Cell Death-Ligand-1 expression in Bladder Schistosomal Squamous Cell Carcinoma – There’s room for Immune Checkpoint Blockage?
por: Madureira, Ana C.
Publicado: (2022)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Yu, Wei-Bo, et al.
Publicado: (2019)

Corrigendum: Decreased expression of programmed death ligand-L1 by seven in absentia homolog 2 in cholangiocarcinoma enhances T-cell–mediated antitumor activity
por: Zheng, Hao, et al.
Publicado: (2022)

Formation of eruptive cutaneous squamous cell carcinomas after programmed cell death protein-1 blockade
por: Marsh, Rachel L., et al.
Publicado: (2020)

Concurrent development of high-stage cutaneous squamous cell carcinoma during complete response of metastatic cutaneous squamous cell carcinoma to programmed cell death protein 1 blockade with cemiplimab
por: Siegel, Jacob D., et al.
Publicado: (2021)

Clinicopathological Features of Programmed Cell Death-ligand 1 Expression in Patients with Oral Squamous Cell Carcinoma
por: Cui, Yong-Xin, et al.
Publicado: (2020)

Effect of Programmed Death-Ligand 1 in Cancer-Associated Fibroblasts on Advanced Laryngeal Squamous Cell Carcinoma
por: Yang, Zhendong, et al.
Publicado: (2021)

Cbl-b Deficiency Mediates Resistance to Programmed Death-Ligand 1/Programmed Death-1 Regulation
por: Fujiwara, Mai, et al.
Publicado: (2017)

Antitumor effects of the silencing of programmed cell death ligand 1 in colorectal cancer via immunoregulation
por: Chen, Yilin, et al.
Publicado: (2018)

The Role of the Immune System in Cutaneous Squamous Cell Carcinoma
por: Bottomley, Matthew J., et al.
Publicado: (2019)

Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas
por: Yang, Min-Wei, et al.
Publicado: (2019)

The programmed death ligand 1 interactome demonstrates bidirectional signaling coordinating immune suppression and cancer progression in head and neck squamous cell carcinoma
por: Nieto, Cera, et al.
Publicado: (2023)

Commentary on “Clinicopathological features of programmed cell death-ligand 1 expression in patients with oral squamous cell carcinoma”
por: Peña-Cardelles, Juan Francisco, et al.
Publicado: (2022)

Programmed Death-Ligand 1-Positive Squamous Cell Carcinoma Spontaneously Regressed after Percutaneous Needle Biopsy
por: Sasahara, Masayuki, et al.
Publicado: (2023)

Evaluation of Programmed Death - Ligand 1 (Pd-L1) Expression in Head and Neck Squamous Cell Carcinoma
por: Unnikrishnan, Aarya, et al.
Publicado: (2023)

Soluble programmed death-1 (sPD-1) and programmed death ligand 1 (sPD-L1) as potential biomarkers for the diagnosis and prognosis of glioma patients
por: Liu, Shujun, et al.
Publicado: (2020)

Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes
por: Liao, Haotian, et al.
Publicado: (2019)

Recent Findings in the Regulation of Programmed Death Ligand 1 Expression
por: Shen, Xiangfeng, et al.
Publicado: (2019)

γδ T cell costimulatory ligands in antitumor immunity
por: McGraw, Joseph M., et al.
Publicado: (2022)

Programmed Death Ligand 2 in Cancer-Induced Immune Suppression
por: Rozali, Esdy N., et al.
Publicado: (2012)

Digital Slides as an Effective Tool for Programmed Death Ligand 1 Combined Positive Score Assessment and Training: Lessons Learned from the “Programmed Death Ligand 1 Key Learning Program in Head-and-Neck Squamous Cell Carcinoma”
por: Eccher, Albino, et al.
Publicado: (2021)

Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma
por: Ock, Chan-Young, et al.
Publicado: (2017)

Programmed death‐ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor
por: Zhang, Wencheng, et al.
Publicado: (2017)

Cisplatin‐induced programmed cell death ligand‐2 expression is associated with metastasis ability in oral squamous cell carcinoma
por: Sudo, Shunichi, et al.
Publicado: (2020)

Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma
por: Li, Ying-Fei, et al.
Publicado: (2017)

Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma
por: Chandrasekaran, Deepika, et al.
Publicado: (2019)

Paraneoplastic Pemphigus Revealed by Anti-programmed Death-1 Pembrolizumab Therapy for Cutaneous Squamous Cell Carcinoma Complicating Hidradenitis Suppurativa
por: Yatim, Ahmad, et al.
Publicado: (2019)

Immune Checkpoint Gene Expression Profiling Identifies Programmed Cell Death Ligand-1 Centered Immunologic Subtypes of Oral and Squamous Cell Carcinoma With Favorable Survival
por: Yu, Yang, et al.
Publicado: (2022)

Regulation of programmed cell death ligand 1 expression by atypical protein kinase C lambda/iota in cutaneous angiosarcoma
por: Kawamura, Ai, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8qu8qa5nhmfkpu20grkg175kuv